Targeting Transcription Factors in Cancer

Trends in Cancer

Volumn 1, Issue 1, 2015, Pages 53-65

  Bhagwat, Anand S ^a   Vakoc, Christopher R ^a  

^a Cold Spring Harbor Laboratory ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BRD4 PROTEIN; CORE BINDING FACTOR BETA; ESTROGEN; GLUCOCORTICOID RECEPTOR; MASTERMIND LIKE PROTEIN; NOTCH1 RECEPTOR; PHTHALIMIDE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; PROTEIN BCL 6; PROTEIN MDM2; PROTEIN P53; RARA PROTEIN; RETINOIC ACID; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CELL TRANSFORMATION; DRUG MECHANISM; DRUG TARGETING; GENE REPRESSION; LIGAND BINDING; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; PROSTATE CANCER; REVIEW; T CELL LEUKEMIA; THERAPEUTIC INDEX;

EID: 84957798869     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2015.07.001     Document Type: Review

References (100)

1. C. Yan, and P.J. Higgins Drugging the undruggable: transcription therapy for cancer Biochim. Biophys. Acta 1835 2013 76 85
2. T.I. Lee, and R.A. Young Transcriptional regulation and its misregulation in disease Cell 152 2013 1237 1251
3. J.E. Darnell Jr. Transcription factors as targets for cancer therapy Nat. Rev. Cancer 2 2002 740 749
4. E.Y. Lee, and W.J. Muller Oncogenes and tumor suppressor genes Cold Spring Harb. Perspect. Biol. 2 2010 a003236
5. G. Bretones, and et al. Myc and cell cycle control Biochim. Biophys. Acta 1849 2015 506 516
6. L.A. Garraway, and E.S. Lander Lessons from the cancer genome Cell 153 2013 17 37
7. K.L. Rice, and H. de The The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies J. Intern. Med. 276 2014 61 70
8. H. de The, and et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus Nature 347 1990 558 561
9. Z.Y. Wang, and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood 111 2008 2505 2515
10. M.E. Huang, and et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood 72 1988 567 572
11. M.E. Huang, and et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases Chin. Med. J. (Engl.) 100 1987 949 953
12. F. Lo-Coco, and et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia N. Engl. J. Med. 369 2013 111 121
13. R.J. Lin, and et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 391 1998 811 814
14. J.H. Martens, and et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia Cancer Cell 17 2010 173 185
15. A. Illendula, and et al. A small-molecule inhibitor of the aberrant transcription factor CBFbeta-SMMHC delays leukemia in mice Science 347 2015 779 784
16. M.F. de Bruijn, and N.A. Speck Core-binding factors in hematopoiesis and immune function Oncogene 23 2004 4238 4248
17. S.M. Lukasik, and et al. Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis Nat. Struct. Biol. 9 2002 674 679
18. N.C. Nicolaides, and et al. The human glucocorticoid receptor: molecular basis of biologic function Steroids 75 2010 1 12
19. H. Inaba, and C.H. Pui Glucocorticoid use in acute lymphoblastic leukaemia Lancet Oncol. 11 2010 1096 1106
20. C.H. Pui, and W.E. Evans Treatment of acute lymphoblastic leukemia N. Engl. J. Med. 354 2006 166 178
21. Z. Wang, and et al. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis J. Biol. Chem. 278 2003 23861 23867
22. M.T. Abrams, and et al. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA J. Biol. Chem. 279 2004 55809 55817
23. D. Jing, and et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells Blood 125 2015 273 283
24. S.W. Paugh, and et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells Nat. Genet. 47 2015 607 614
25. E. Piovan, and et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia Cancer Cell 24 2013 766 776
26. C.G. Mullighan, and et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia Nature 471 2011 235 239
27. N. Pottier, and et al. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia J. Natl. Cancer Inst. 100 2008 1792 1803
28. M.J. Duffy, and et al. p53 as a target for the treatment of cancer Cancer Treat. Rev. 40 2014 1153 1160
29. W. Xue, and et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature 445 2007 656 660
30. A. Ventura, and et al. Restoration of p53 function leads to tumour regression in vivo Nature 445 2007 661 665
31. Q. Zhang, and et al. Targeting p53-MDM2-MDMX loop for cancer therapy Subcell. Biochem. 85 2014 281 319
32. L.T. Vassilev, and et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
33. B. Huang, and et al. Estrogen receptors in breast carcinogenesis and endocrine therapy Mol. Cell. Endocrinol. 2014 10.1016/j.mce.2014.11.015 Published online November 26, 2014
34. M. van Kruchten, and et al. PET imaging of oestrogen receptors in patients with breast cancer Lancet Oncol. 14 2013 e465 e475
35. B. Manavathi, and et al. Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development Front. Cell Dev. Biol. 2 2014 34
36. H.R. Lee, and et al. Functions and physiological roles of two types of estrogen receptors, ERalpha and ERbeta, identified by estrogen receptor knockout mouse Lab. Anim. Res. 28 2012 71 76
37. R.S. Mehta, and et al. Combination anastrozole and fulvestrant in metastatic breast cancer N. Engl. J. Med. 367 2012 435 444
38. B.S. Komm, and S. Mirkin An overview of current and emerging SERMs J. Steroid Biochem. Mol. Biol. 143 2014 207 222
39. A. Howell Pure oestrogen antagonists for the treatment of advanced breast cancer Endocr. Relat. Cancer 13 2006 689 706
40. A.L. Wijayaratne, and D.P. McDonnell The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators J. Biol. Chem. 276 2001 35684 35692
41. P.E. Goss, and et al. Exemestane for breast-cancer prevention in postmenopausal women N. Engl. J. Med. 364 2011 2381 2391
42. A.M. Scherbakov, and et al. Molecular mechanisms of hormone resistance of breast cancer Bull. Exp. Biol. Med. 155 2013 384 395
43. Q. Tang, and et al. A comprehensive view of nuclear receptor cancer cistromes Cancer Res. 71 2011 6940 6947
44. C.S. Ross-Innes, and et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer Nature 481 2012 389 393
45. J.S. Carroll, and et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1 Cell 122 2005 33 43
46. M. Lupien, and et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance Genes Dev. 24 2010 2219 2227
47. + breast cancer-an evolving field Ecancermedicalscience 9 2015 523
48. C.K. Osborne, and R. Schiff Mechanisms of endocrine resistance in breast cancer Annu. Rev. Med. 62 2011 233 247
49. H.L. Franco, and et al. TNFalpha signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome Mol. Cell 58 2015 21 34
50. P.Y. Hsu, and et al. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer Cancer Cell 24 2013 197 212
51. M.M. Shen, and C. Abate-Shen Molecular genetics of prostate cancer: new prospects for old challenges Genes Dev. 24 2010 1967 2000
52. C. Huggins, and et al. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland Arch. Surg. 43 1941 209 223
53. B.S. Carver Strategies for targeting the androgen receptor axis in prostate cancer Drug Discov. Today 19 2014 1493 1497
54. N.L. Sharma, and et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man Cancer Cell 23 2013 35 47
55. J.W. Moul Utility of LHRH antagonists for advanced prostate cancer Can. J. Urol. 21 2014 22 27
56. J.S. de Bono, and et al. Abiraterone and increased survival in metastatic prostate cancer N. Engl. J. Med. 364 2011 1995 2005
57. C.J. Ryan, and et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N. Engl. J. Med. 368 2013 138 148
58. A.W. Wyatt, and M.E. Gleave Targeting the adaptive molecular landscape of castration-resistant prostate cancer EMBO Mol. Med. 20 2015 878 894
59. J.B. Aragon-Ching The evolution of prostate cancer therapy: targeting the androgen receptor Front. Oncol. 4 2014 295
60. C. Tran, and et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
61. J.D. Joseph, and et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509 Cancer Discov. 3 2013 1020 1029
62. M. Korpal, and et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) Cancer Discov. 3 2013 1030 1043
63. M.D. Balbas, and et al. Overcoming mutation-based resistance to antiandrogens with rational drug design Elife 2 2013 e00499
64. E.S. Antonarakis, and et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N. Engl. J. Med. 371 2014 1028 1038
65. Y. Chen, and et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss Nat. Med. 19 2013 1023 1029
66. J. Yu, and et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression Cancer Cell 17 2010 443 454
67. V.K. Arora, and et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Cell 155 2013 1309 1322
68. J.C. Aster, and et al. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies J. Pathol. 223 2011 262 273
69. R.E. Moellering, and et al. Direct inhibition of the NOTCH transcription factor complex Nature 462 2009 182 188
70. K. Hatzi, and A. Melnick Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis Trends Mol. Med. 20 2014 343 352
71. L.C. Cerchietti, and et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo Cancer Cell 17 2010 400 411
72. J. Shi, and C.R. Vakoc The mechanisms behind the therapeutic activity of BET bromodomain inhibition Mol. Cell 54 2014 728 736
73. J.S. Roe, and et al. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia Mol. Cell 58 2015 1028 1039
74. B. Chapuy, and et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma Cancer Cell 24 2013 777 790
75. I.A. Asangani, and et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer Nature 510 2014 278 282
76. P. Filippakopoulos, and et al. Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
77. E. Nicodeme, and et al. Suppression of inflammation by a synthetic histone mimic Nature 468 2010 1119 1123
78. J. Loven, and et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers Cell 153 2013 320 334
79. J.E. Delmore, and et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 146 2011 904 917
80. J. Zuber, and et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 478 2011 524 528
81. K.M. Bernt, and S.A. Armstrong A role for DOT1L in MLL-rearranged leukemias Epigenomics 3 2011 667 670
82. N. Kwiatkowski, and et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor Nature 511 2014 616 620
83. X.W. Zhang, and et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML Science 328 2010 240 243
84. M. Jeanne, and et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3 Cancer Cell 18 2010 88 98
85. V. Lallemand-Breitenbach, and et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway Nat. Cell Biol. 10 2008 547 555
86. M.H. Tatham, and et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation Nat. Cell Biol. 10 2008 538 546
87. J. Zhu, and et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins Proc. Natl. Acad. Sci. U.S.A. 96 1999 14807 14812
88. S. Wei, and et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer Nat. Med. 21 2015 457 466
89. J. Ablain, and et al. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies J. Exp. Med. 210 2013 647 653
90. J. Ablain, and et al. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure Nat. Med. 20 2014 167 174
91. T. Ito, and et al. Identification of a primary target of thalidomide teratogenicity Science 327 2010 1345 1350
92. J. Kronke, and et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells Science 343 2014 301 305
93. G. Lu, and et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins Science 343 2014 305 309
94. E.S. Fischer, and et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide Nature 512 2014 49 53
95. P.P. Chamberlain, and et al. Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs Nat. Struct. Mol. Biol. 21 2014 803 809
96. G.E. Winter, and et al. Phthalimide conjugation as a strategy for in vivo target protein degradation Science 348 2015 1376 1381
97. A.N. Koehler A complex task? Direct modulation of transcription factors with small molecules Curr. Opin. Chem. Biol. 14 2010 331 340
98. T. Wang, and et al. Genetic screens in human cells using the CRISPR-Cas9 system Science 343 2014 80 84
99. O. Shalem, and et al. Genome-scale CRISPR-Cas9 knockout screening in human cells Science 343 2014 84 87
100. J. Shi, and et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains Nat. Biotechnol. 33 2015 661 667